What is Emergent Biosolutions's net change in cash?

Emergent Biosolutions (EBS) reported net change in cash of -$47.6M in Q1 2026.

How has Emergent Biosolutions's net change in cash changed year-over-year?

Emergent Biosolutions's net change in cash decreased by 200.8% year-over-year, from $47.2M to -$47.6M.

What is the long-term trend for Emergent Biosolutions's net change in cash?

Over 2 years (2022 to 2024), Emergent Biosolutions's net change in cash has grown at a -69.7% compound annual growth rate (CAGR), from $66.3M to -$6.1M.

What does net change in cash mean?

Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Emergent Biosolutions EBS Net Change in Cash

Net Change in Cash at other companies

Thermo Fisher ScientificTMO

-$6.6B-5,099%

Regeneron PharmaceuticalsREGN

-$153.1M-125%

AMP

Amphastar PharmaceuticalsAMPH

$762K-97.6%

Amneal Pharmaceuticals, Inc.AMRX

-$108.53M-117%

CorMedixCRMD

$33.25M+29.7%

Collegium Pharmaceutical, Inc.COLL

$37.4M+82.6%

Other financials

Income statement

See full

Revenue$156.1M-29.7%

Gross profit$84.1M-37.1%

Operating income$10.5M-79.0%

Net income$6.8M-90.0%

EPS (diluted)$0.07-94.1%

Balance sheet

See full

Cash & equivalents$161.5M+5.7%

Total debt$584.6M-13.1%

Total equity$523.1M-5.4%

Total assets$1.3B-7.4%

Cash flow

See full

Operating cash flow-$33.8M-202%

CapEx$2.4M-33.3%

Free cash flow-$36.2M-145%

Valuation

See full

Market cap$411.74M+22.0%

Enterprise value$834.84M-2.6%

P/E3.6×—

P/S0.6×+0.3×

Profitability

See full

Gross margin54.2%+19.0pp

Operating margin15%+10.3pp

Net margin9.6%+5.8pp

FCF margin20.8%—

Returns & leverage

See full

Return on equity13.9%+8.1pp

Debt / equity1.1×-0.1×

Current ratio4.3×-2.0×

Where this comes from

Reported directly by Emergent Biosolutions in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Emergent Biosolutions's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Emergent Biosolutions's net change in cash?: Emergent Biosolutions (EBS) reported net change in cash of -$47.6M in Q1 2026.
How has Emergent Biosolutions's net change in cash changed year-over-year?: Emergent Biosolutions's net change in cash decreased by 200.8% year-over-year, from $47.2M to -$47.6M.
What is the long-term trend for Emergent Biosolutions's net change in cash?: Over 2 years (2022 to 2024), Emergent Biosolutions's net change in cash has grown at a -69.7% compound annual growth rate (CAGR), from $66.3M to -$6.1M.
What does net change in cash mean?: Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.